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Abstract 
Mild cognitive impairment (MCI) is a diagnosis frequently used in dementia 
research and in memory clinics. MCI is meant to identify patients without 
dementia, but with cognitive decline beyond what is considered normal, and 
with an increased risk of progressing to dementia. Typically, cognitive test 
performance 1.5 standard deviations (SD) or more below normal controls is 
considered impaired. To account better for heterogeneity in etiology and 
prognosis in MCI, clinical subtypes of MCI have been suggested; MCI with 
or without memory impairment as one dimension, and impairment in one or 
more than one cognitive domain as another dimension. The aim of this thesis 
is to clarify the prognostic value of MCI and MCI subtypes in memory-clinic 
patients. 
All participants in papers I-III were either patients seeking care at the 
Sahlgrenska memory clinic in Mölndal, or healthy controls examined at the 
same unit.  
Paper I included 317 patients, 55 of whom progressed to dementia. Paper II 
included 358 patients, 68 of whom progressed to dementia. Paper III included 
383 patients, 70 of whom progressed to dementia. All patients included in 
paper I were also included in papers II and III, all patients included in paper 
II were also included in paper III. 
In paper I, 317 patients were followed for 2 years, and 168 patients were 
followed for 4-6 years. The probability of a patient progressing to dementia 
after 2 years was 17%, and 14% after 4-6 years.  One-third of the memory-
clinic patients did not meet standard criteria for MCI at baseline, and had a 
reduced probability of progressing to dementia (from 17% to 1% within 2 
years and from 14% to 9% after 4-6 years). Meeting standard criteria for MCI 
only slightly increased the risk of progressing to dementia (from 17% to 26% 
after 2 years and from 14% to 20% after 4-6 years). Amnestic multi-domain 
MCI was the only subtype that significantly increased a patient’s probability 
of progressing to dementia (from 18% to 46% after 2 years and from 14% to 
37% after 4-6 years). A more liberal MCI cut-off (i.e. 1.0 SD instead of 1.5 
SD or 2.0 SD) did not improve the prognostic accuracy of MCI or the MCI 
subtypes.  
In paper II, amnestic multi-domain MCI was associated with a much larger 
increase in probability of progression to dementia in younger patients under 
65 with more than 12 years of education than in other demographic groups, 
as compared with patients with other subtypes and those who did not meet 
MCI criteria.  
In paper III, cognitive subtypes derived from a latent profile analysis 
differentiated between patients who two years after baseline progressed to 
Alzheimer's disease dementia vs. dementia with subcortical vascular features, 
where the traditional MCI subtypes did not. 
In conclusion, a large group of memory-clinic patients do not display 
significant cognitive impairments and have a very low probability of 
progressing to dementia. Prognosticating progression to dementia is easier in 
younger patients with more years of education than in other demographic 
groups. However, even among younger patients with more years of 
education, it may be better to use absence of amnestic multi-domain MCI to 
rule out progression to dementia, than to use presence of amnestic multi-
domain MCI to find patients who will progress. Statistically derived 
cognitive subtypes may separate the risk of AD dementia from the risk of 
dementia with subcortical vascular features where the established MCI 
subtypes do not. 
Keywords: mild cognitive impairment, cognition, dementia, Alzheimer's 
disease, memory clinic, diagnostic assessment. 
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 Sammanfattning på svenska 
Lindrig kognitiv störning, eller mild cognitive impairment (MCI) på 
engelska, är en diagnos framtagen för att på ett tidigt stadium identifiera 
personer som har en förhöjd risk för att utveckla demens. Lindrig kognitiv 
störning kan delas in i undergrupper baserat på vilken sorts kognitiv 
nedsättning en patient har, samt om patienten har flera olika sorters 
nedsättningar eller inte. Generellt brukar en nedsättning i förmågan att lära in 
och komma ihåg nytt material, en minnesstörning, vara förknippad med en 
högre risk för att utveckla demens jämfört med andra sorters nedsättningar, 
särskilt om minnesnedsättningen framträder i kombination med andra sorters 
kognitiva nedsättningar. Flera olika nivåer av nedsättning kan användas för 
att bedöma om en person har lindrig kognitiv störning eller inte, och ett syfte 
med den här avhandlingen var att utvärdera om någon nivå är bättre än de 
andra. Ett andra syfte var att undersöka om den ökade risken för framtida 
demens som lindrig kognitiv störning innebär är lika stor bland äldre och 
yngre personer, och bland personer med högre och lägre utbildningsnivå. Ett 
tredje syfte var att med hjälp av statistiska metoder undersöka vilka kognitiva 
undergrupper som faktiskt är vanliga bland patienter som söker vård på en 
minnesmottagning, eftersom de undergrupper som oftast används är skapade 
utifrån teoretiska antaganden. 
Studierna i avhandlingen är baserade på undersökningar av patienter vid 
minneskliniken på Sahlgrenska universitetssjukhuset, och friska 
kontrollpersoner. Studierna visade att patienter på en minnesmottagning som 
inte uppvisar tydliga kognitiva nedsättningar jämfört med friska äldre 
personer sannolikt inte utvecklar demens inom de närmaste åren. Bland 
patienter på en minnesmottagning är det lättare att ge en korrekt prognos till 
dem som är yngre än 65 och har mer än 12 års utbildning, än till andra 
patienter. Undergrupper framtagna med hjälp av statistiska metoder är bättre 
än de teoretisk framtagna undergrupperna på att skilja mellan patienter som 
kommer att utveckla demens orsakad av Alzheimers sjukdom och demens 
orsakad av småkärlssjukdom. 
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Abbreviations 
AD Alzheimer's disease 
ADL Activities of daily living 
ADNI Alzheimer's disease neuroimaging initiative 
aMCI-md Amnestic multi-domain mild cognitive impairment 
aMCI-sd Amnestic single-domain mild cognitive impairment 
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MixD Mixed dementia, in this thesis a mix of AD and SVD 
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PPV Positive predictive value 
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TN True negative observations 
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VaD Vascular dementia 
VaD-S Dementia with subcortical vascular features (MixD + SVD) 
VOSP Visual Object and Space Perception battery 
WAIS-III Wechsler Adult Intelligence Scale third edition 
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Definitions in short 
Biomarker A characteristic that is objectively measured 
and evaluated as an indicator of normal 
biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic 
intervention. 
Dementia A syndrome characterized by a decline in 
cognitive functions severe enough to interfere 
with independence in daily life. Can have 
different causes. 
Diagnosis Disease classification based on signs and 
symptoms. Typically used to guide treatment 
decisions and to give prognostic estimates. 
Episodic memory Memory of personally experienced events, in 
dementia research usually operationalized as 
the delayed recall of word lists or stories. 
Etiology Cause or causes of a disease. 
False negative An incorrect indication of the absence of a 
target condition, based on a binary diagnostic 
test, i.e. a sick person incorrectly identified as 
healthy. 
False positive An incorrect indication of the presence of a 
target condition, based on a binary diagnostic 
test, i.e. a healthy person incorrectly identified 
as sick. 
Mild cognitive impairment A syndrome characterized by a recent decline 
in cognitive functions greater than that of 
comparable peers, and different from mild 
dementia in that activities of daily life are 
intact or only minimally disturbed. 
Memory clinic Secondary-care facility, usually outpatient, 
where people concerned about their cognitive 
viii 
functioning and progression to dementia are 
remitted. 
Negative likelihood ratio Describes the change in odds of progressing 
to dementia for a patient with a negative test 
result, as compared with the odds among all 
patients. 
Negative predictive value The number of true negatives divided by the 
sum of the number of false negatives and true 
negatives, or the ratio of true negative test 
results to all negative test results. 
Positive likelihood ratio Describes the change in odds of progressing 
to dementia for a patient with a positive test 
result, as compared with the odds among all 
patients. 
Positive predictive value The number of true positives divided by the 
sum of the number of true positives and false 
positives, or the ratio of true positive test 
results to all positive test results. The same as 
post-test probability for a positive test. 
Sensitivity True positive rate, the number of true positive 
observations divided by the number of 
positive observations. 
Sign A clinical manifestation of a disease or 
disorder observed by a clinician. 
Specificity True negative rate, the number of true 
negative observations divided by the number 
of negative observations. 
Symptom A clinical manifestation of a disease or 
disorder observed by the patient. 
Syndrome A condition characterized by a group of signs 
and/or symptoms occurring together. 
ix 
True negative A correct indication of the absence of a target 
condition, based on a binary diagnostic test, 
i.e. a healthy person correctly identified as 
healthy. 
True positive A correct indication of the presence of a target 
condition, based on a binary diagnostic test, 
i.e. a sick person correctly identified as sick. 
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1. Introduction 
Mild cognitive impairment (MCI) is a clinical syndrome, different from 
normal aging in that it entails a recent decline in cognitive function greater 
than that of comparable peers, and different from mild dementia in that 
activities of daily life (ADL) are intact or only minimally disturbed.  
Dementia is also a syndrome, characterized by multiple cognitive deficits 
severe enough to cause impairment in occupational or social functioning [1]. 
In 2015, the estimated number of people suffering from dementia worldwide 
was 47 million, an increase of 11 million since 2010. The worldwide yearly 
costs of dementia have been estimated at 818 billion dollars in 2015. The 
majority of the costs occur in the social sector and in informal care [2]. 
Dementia is among the top 10 conditions contributing to disability worldwide 
[3]. 
Alzheimer's disease (AD) is the most common cause of dementia [4]. 
Clinically, AD dementia is typically characterized by severely impaired 
episodic memory, with impaired test results on delayed recall and 
recognition. In AD dementia, impairments in naming ability, verbal fluency, 
executive functions, and visuospatial functions are also commonly observed 
[5]. 
Aggregation of intracellular tau protein in neurofibrillary tangles and extra 
cellular aggregation of beta amyloid protein into plaques can be observed on 
autopsy [6] and are regarded as the cause of AD [7]. Measuring total tau (T-
tau), phosphorylated tau (P-tau), and β-amyloid protein (Aβ1-42) in 
cerebrospinal fluid (CSF) provides an in vivo estimate of the underlying 
pathologies, and can help differentiate healthy controls from persons with 
both incipient [8] and manifest AD dementia [8,9]. As of yet, no treatments 
targeting amyloid plaques have reached clinical endpoints, and only 
symptomatic treatments are available for AD dementia. 
Another common cause of dementia is vascular disease, e.g. stroke, resulting 
in vascular dementia (VaD). At the Sahlgrenska memory clinic (the clinical 
setting for this thesis), stroke related VaD is very uncommon. Subcortical 
vascular disease, or small vessel disease, in which blood flow in deep brain 
tissue is compromised, leading to white-matter lesions and micro infarctions, 
is a sometimes overlooked vascular condition [10], but is also an important 
cause of dementia [11]; subcortical vascular dementia dementia (SVD). In 
many cases, subcortical vascular lesions and AD pathology are both present 
and both contribute to the emergence of cognitive symptoms and subsequent 
Mild cognitive impairment - concepts, cut-offs, and clinical relevance 
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dementia. Incipient SVD is separable from non-progressing MCI using 
neurofilament light, and has a different profile of T-tau, P-tau, and Aβ1-42 
than incipient AD dementia [12].  
Carrying the apolipoprotein E (APOE) ε4 allele is the greatest known genetic 
risk factor for sporadic AD dementia [13]. Carrying the APOE ε4 allele is 
also associated with an increased risk for cerebral amyloid angiopathy, 
common in elderly people with dementia and associated with white-matter 
lesions [14]. 
Other dementia disorders include Lewy-body dementia, and frontotemporal 
dementia, but a dementia syndrome can be caused by almost any disease or 
injury affecting the brain (e.g. HIV, Parkinson's disease, head trauma, 
substance abuse) [1]. 
1.1.1 Mild cognitive impairment 
In 1982, Reisberg used the term 'mild cognitive decline' [15], and later 'mild 
cognitive impairment' [16], when describing stage 3 of the Global 
Deterioration Scale (GDS), meant as a description of global clinical severity 
of the stages of Alzheimer's disease. In 1999, Petersen proposed criteria for 
MCI [17], where memory complaints and abnormal memory for age were 
mandatory for the category of MCI. Table 1. Other cognitive domains were 
not yet mentioned, other than stipulating "normal general cognitive function". 
Here, the first mention of a cut-off for impaired memory was made in the 
context of MCI, albeit descriptive and not normative. A cohort of patients 
with MCI were reported to perform around 1.5 standard deviations below the 
level of age-matched and education-matched controls on a test of episodic 
memory.  
In 2001, Petersen [18] stated that  
“All individuals who present clinically with mild cognitive symptoms may not 
share the same fate ultimately. Some may go on to develop AD, while others 
may progress to another dementia. It is possible that some of the subjects will 
never progress to any significant extent. This broad group of individuals with 
mild cognitive complaints could be considered as having MCI. Recognizing 
that there are multiple sources of heterogeneity in such a classification, it is 
desirable to further specify criteria for subsets of MCI.” 
recognizing that the general phenotype of MCI may be too inclusive for the 
purpose of identifying patients likely to progress to AD dementia. This was 
one of the reasons for the introduction of four syndromal phenotypes, or 
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subtypes, of MCI; MCI with or without memory impairment as one 
dimension, and impairment in one or more than one cognitive domain as 
another dimension, later formalized by the International Working Group on 
Mild Cognitive Impairment [19,20]. The new classification used the 
categories amnestic single domain MCI (aMCI-sd), amnestic multi-domain 
MCI (aMCI-md), non-amnestic single domain MCI (naMCI-sd), and non-
amnestic multi-domain MCI (naMCI-md). 
Still, no strict cut-off for MCI was recommended, although 1.5 standard 
deviations was mentioned again. In 2009, Jak et al. [21] sought to 
characterize various diagnostic approaches better. They described four 
operationalizations of MCI; historical criteria (one or more memory test 
scores 1.5 SD below age appropriate norms), typical criteria (one or more test 
scores 1.5 SD below age-appropriate norms), comprehensive criteria (two or 
more test scores 1.0 SD or more below age-appropriate norms), and liberal 
criteria (one test score 1.0 SD or more below age-appropriate norms), all 
based on neuropsychological test results. Table 2. 
In the fifth version of the Diagnostic and Statistical Manual of Mental 
Disorders [22], regardless of etiology, the terms MCI and dementia were 
replaced with Mild and Major Neurocognitive Disorder, respectively. The 
suggested range for Mild neurocognitive disorder, equivalent to MCI, was 
described as typically in the range of 1.0–2.0 SD below appropriate norms, in 
one or more cognitive domains. Primarily subtyped according to known or 
presumed etiology, "on the basis of a combination of time course, 
characteristic domains affected, and associated symptoms." Further criteria 
incorporating biomarkers intended to identify prodromal AD have been 
suggested, but without making use of the subtype paradigm. In 2011, Albert 
et al. [23] suggested "Objective evidence of impairment in one or more 
cognitive domains, typically including memory". In 2014, Dubois et al. [24] 
suggested episodic memory impairments, without mention of other cognitive 
domains. 
Criteria for the diagnosis of mild cognitive disorders resulting from vascular 
disease (vascular cognitive impairment, VCI) have recently been proposed by 
the International Society of Vascular Behavioural and Cognitive Disorders 
(VASCOG) [25], with impairments in at least one of seven cognitive 
domains, either with "test performance ... typically in the range between 1 
and 2 standard deviations below appropriate norms (or between the 3rd and 
16th percentiles)", or equivalent level as judged by a clinician, in 
combination with evidence of a predominantly vascular etiology. Published 
consensus guidelines have suggested a brief neuropsychological test battery 
Mild cognitive impairment - concepts, cut-offs, and clinical relevance 
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to diagnose VCI [26], and the importance of studying etiological VaD 
subtypes such as subcortical small vessel disease have recently been 
highlighted [27]. However, there is to date no broad consensus concerning 
syndromal presentations in mild stages of either AD or VaD, or if MCI 
should be diagnosed based on neuropsychological test results or clinical 
judgment, or what cut-off should be employed if neuropsychological test 
results form the basis of the diagnosis. 
 
Table 1. Clinical criteria for the MCI syndrome 
 Petersen, 
1999 [17] 
Winblad, 
2004 [20] 
Albert, 
2011 [23] 
DSM-5, 
2013 [22] 
Criteria     
Self-reported or informant-
reported memory complaint X    
Self-reported or informant-
reported cognitive complaint  X X X 
Objective memory 
impairment X    
Objective cognitive 
impairment  X X X 
Essentially preserved general 
cognitive functioning X    
Preserved independence in 
functional abilities X X X X 
No dementia X X X X 
Abbreviations: X, criterion required for diagnosis; DSM-5, Diagnostic and Statistical 
Manual of Mental Disorders, 5th edition. 
Table modified from Petersen, 2014 [28]. 
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Table 2. Operationalizations of MCI criteria 
 
Historical 
criteria 
Typical 
criteria 
Comprehensive 
criteria 
Liberal 
criteria 
Conservative 
criteria 
Cognitive 
domain Memory Any Any Any Any 
n of tests 
under cut-off 
required for 
MCI ≥1 
≥1 per 
domain ≥2 per domain 
≥1 per 
domain 
≥1 in ≥2 
domains 
Cut-off (SD) 1.5 1.5 1 1 1.5 
Abbreviations: n, number; MCI, mild cognitive impairment; SD, standard deviation.  
Operationalizations adapted from Jak et al. [21]. 
 
In parallel with the development of the MCI concept, several other similar 
concepts have been described. Kral's state of "benign senescent 
forgetfulness" was characterized by the inability to recall "relatively 
unimportant data", accompanied by lower scores on a memory test as 
compared with their age-group, between normal memory function and 
'malignant senescent forgetfulness', which today might be called dementia or 
major neurocognitive disorder [29]. In 1986, a working group suggested a 
new diagnostic term for a decline in memory in healthy older individuals, and 
called it Age-Associated Memory Impairment [30]. Memory test 
performance at least 1 SD below the mean of young adults was one of the 
criteria, in contrast to Kral’s concept, which compared individuals with 
others of the same age.  
In the ICD-10 research criteria presented in 1993 [31], Mild Cognitive 
Disorder was introduced, and comprised difficulties in learning, recall, 
concentration, thinking, or language, and abnormal performance on 
neuropsychological tests, as well as 'evidence and/or history of cerebral 
disease, damage or dysfunction, or of systemic physical disorder known to 
cause cerebral dysfunction'. This category was intended to capture persons 
with significant cognitive decline who did not have dementia. 
In 1994, Levy et al. proposed the concept of Aging-associated cognitive 
decline (AACD) [32], intended to identify persons who did not fulfill criteria 
for Mild Cognitive Disorder. The criteria were similar, but instead of the 
presence required the absence of cerebral disease, damage, or dysfunction or 
of systemic physical disorder known to cause cerebral dysfunction. Cognitive 
Mild cognitive impairment - concepts, cut-offs, and clinical relevance 
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performance at least 1 SD below appropriate norms, in one of the cognitive 
domains memory and learning; attention and concentration; thinking, 
language, or visuospatial functioning [32], was required.  
In 1997, another competing concept was introduced by Graham et al. They 
called it cognitive impairment, no dementia, or CIND [33]. CIND was based 
on the population study The Canadian Study of Health and Aging, and was 
diagnosed in the absence of dementia, and consisted of the sub-categories 
delirium, chronic alcohol and drug use, depression, psychiatric illness, mental 
retardation, circumscribed or limited memory impairment, and "other" 
cognitive impairments. 
MCI is by far the most commonly used term according to a search in 
Title/Abstract on PubMed. Table 3. 
 
Table 3. PubMed search for MCI and related terms (2019-03-19) 
Term, in Title/Abstract on PubMed.gov n 
Mild cognitive impairment 14350 
Mild cognitive impairment OR MCI 21696 
Cognitive impairment, no dementia OR CIND 361 
Senescent forgetfulness 21 
Age-Associated Memory Impairment OR AAMI 648 
Mild cognitive disorder 58 
Aging-associated cognitive decline OR AACD 101 
Mild neurocognitive disorder 113 
Abbreviations: MCI, mild cognitive impairment; CIND, cognitive impairment, 
no dementia; AAMI, age-associated memory impairment; AACD, aging-
associated cognitive decline. 
 
1.2 Prognostic accuracy of MCI 
Early clinical studies suggested that MCI defined using the original Petersen 
criteria from 1999 [17] (amnestic MCI; aMCI) in the majority of cases would 
progress to AD dementia [17,34], and MCI has been suggested as a valid 
target population for treatment trials [18,35]. A later meta-analysis reported  a 
yearly progression rate of 10% and a cumulative progression to all-cause 
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dementia of 39% in specialist memory clinic settings [36] using the Petersen 
MCI criteria from 1999 [17]. Corresponding figures in community samples 
with MCI were an annual progression rate of 5% and 22% total progression 
to all-cause dementia. The mean observation time for the combined clinical 
and community samples was 4.6 years (SD 2.1). Farias et al. reported a 
yearly conversion rate of 13% in a memory clinic sample and 3% in a 
community sample [37], both groups fulfilling the updated MCI criteria from 
2004 [20]. The annual conversion rate to dementia may decrease over time 
[34,36,38], perhaps reflecting the heterogeneity of MCI [39]; some MCI 
patients have incipient dementia and progress quickly, others may have other 
underlying reasons for their cognitive impairments and will not progress to 
dementia; some may even improve over time [38]. 
Many studies published on the topic of predicting dementia in memory-clinic 
patients with MCI have not reported sensitivity, specificity, and related 
parameters, nor true positive, false positive, true negative, and false negative 
observations [40-51], making it difficult to say how well the construct of 
MCI actually performs as a predictor of dementia.  
Visser et al. reported sensitivity of 66% and a specificity of 73% for 
progression to AD dementia after 5 years for aMCI [52], and a sensitivity of 
78% and a specificity of 74% also for aMCI with progression to AD 
dementia after 5 years, in a different sample [53]. 
1.2.1 Prognostic accuracy of MCI subtypes 
A few papers reporting the prognostic accuracy of all four established MCI 
subtypes in memory-clinic samples have been published. Generally, aMCI-
md has had the highest prognostic accuracy. Various cut-off levels have been 
used to diagnose MCI subtype, but have not been compared with each other 
regarding prognostic accuracy. Visser and Verhey [53] used Petersen’s 
criteria for aMCI [17], with aMCI-sd and aMCI-md pooled, setting the cut-
off for impairment 1.5 SD below the mean of a reference group. They 
followed 320 patients over 5 years. They reported a sensitivity of 78% and a 
specificity of 74% for AD dementia at follow-up for the aMCI group. 
Sensitivity and specificity for the other subtypes were not reported. Rasquin 
et al. [51] followed 118 memory-clinic patients without dementia for 2 years. 
They defined cognitive impairment as a score lower than the 10th percentile 
of scores in a reference group, equivalent to 1.28 SD, or a Mini-Mental State 
Examination (MMSE) score lower than 80% of the maximum score per item 
used. They reported that aMCI-md had a sensitivity of 65% and a specificity 
of 62% for detecting dementia, and the other categories performed poorly, 
Mild cognitive impairment - concepts, cut-offs, and clinical relevance 
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with very low sensitivities. However, using scores derived from the MMSE, 
which is insensitive to subtle cognitive impairments [54], may have affected 
the results. Nordlund et al. reported a sensitivity of 80% and a specificity of 
79% for progression to all-cause dementia after 2 years for aMCI-md, in an 
earlier and smaller version of the patient sample used in this thesis [55]. 
1.2.2 Demographic differences in prognostic accuracy 
Visser et al. reported that the positive predictive values for various definitions 
of MCI in predicting AD dementia 5 years later were higher in patients older 
than 65 years [52], and attributed their findings to a higher prevalence of pre-
dementia in the older group. The results are somewhat conflicting and can 
also be interpreted as a better prognostic accuracy among younger 
participants. In a larger patient sample from the same memory clinic, Visser 
et al. [53] reported good prognostic accuracy for subsequent AD dementia 
only for aMCI in patients 70–85 years, compared with patients under 55 and 
between 55 and 69. Thus, it is unclear how patient age influences the 
prognostic accuracy in MCI. However, both neuritic plaques and 
neurofibrillary tangles measured post-mortem [56,57], and in-vivo CSF AD-
biomarkers [58] are more weakly associated with an AD diagnosis in older 
people, indicating an increasing difficulty to distinguish between different 
states with increasing age. To the best of our knowledge, the prognostic 
accuracy in different education groups or in age and education levels 
simultaneously has not been investigated in clinical samples. 
1.2.3 Data-driven subtypes of MCI 
The MCI subtypes as suggested by Petersen [19] and Winblad et al. [20] are 
top-down categories, based on clinical experience and observation. As an 
alternative approach, several researchers have attempted to create cognitive 
subgroups of MCI patients based on data, using various data-driven methods 
of analysis.  
Using various types of cluster analysis, several studies have reported between 
3 or 4 cognitive clusters in memory-clinic patients. Some of the studies only 
included cross-sectional data [59-61]. Damian et al. [62] found an amnestic-
executive cluster to predict progression to AD dementia best, Edmonds et al. 
[63] and Bondi et al. [64], both studying the ADNI cohort, found a 
dysexecutive and a dysexecutive/mixed class to predict progression to all-
cause dementia best. 
Four studies using latent profile analysis (LPA) to find latent cognitive 
subtypes in memory-clinic patients have been published. One study was 
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cross-sectional and also included neuropsychiatric features and functional 
impairments in the model [65]. The other three studies reported 3-5 latent 
classes [66-68]. Eppig et al. found a mixed MCI class to be most predictive 
of progression to all-cause dementia [68]. Köhler et al. [66] found a primary 
non-memory impairment class to have the highest prognostic accuracy for 
progression to all-cause dementia, and McGuinness et al. [67] found a class 
with deficits in multiple domains, including memory, to best predict 
progression to all-cause dementia. McGuinness et al. also compared to MCI 
subtypes using typical criteria [21] (Table 2). Of the established MCI 
subtypes, aMCI-md performed best, but was outperformed by their LPA-
derived multiple deficits class. Eppig et al. [68], Köhler et al. [66], and 
McGuinness et al. [67] did not report sensitivity and specificity for 
progression to dementia. 
None of the above studies have reported true positives, false positives, true 
negatives, false negatives, sensitivities, or likelihood ratios, and none have 
investigated progression to dementia with subcortical vascular features. 
1.2.4 Prognostic accuracy of biomarker-based classifications 
Prognostic accuracy of neurochemical biomarkers is typically evaluated in 
patients who fulfill criteria for MCI (Table 4), either the Petersen criteria 
from 1999 [17], which require memory impairments, or later criteria, which 
may also base the MCI categorization on impairments in other cognitive 
domains. 
T-tau, P-tau, and Aβ1-42 can discriminate between manifest AD dementia and 
healthy controls with high sensitivity and specificity [69]. However, 
discriminating between incipient AD dementia and stable MCI, i.e. giving a 
reliable prognosis to a patient, is more difficult. As can be seen in Table 4, 
most attempts to predict progression to AD dementia using CSF biomarkers 
fail to achieve a simultaneously high sensitivity and specificity, even though 
all samples consist of only patients with MCI, and some use optimized cut-
offs derived from the sample under study. In a review of studies predicting 
progression to probable AD dementia, Mitchell et al. found that CSF 
biomarkers, in general, slightly increased the positive predictive value, and 
decreased the negative predictive value as compared with clinical assessment 
alone [70]. 
There is a difference between using pre-defined and optimized cut-offs. 
Optimized cut-offs, obtained typically using ROC analysis, which produce 
the optimal cut-off value to distinguish between two groups on a continuous 
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variable, risk overestimating the prognostic or diagnostic accuracy of the 
marker investigated. A pre-defined cut-off, either derived from a previous 
publication using a different sample, or derived from a training data-set and 
tested in a validation data-set, is preferable. 
Table 4. Sensitivity and specificity of CSF AD biomarkers for 
progression to AD dementia 
Study n Marker Sens./spec. FU-time Cut-off Sample 
Brys, 2009 [71] 65 P-tau 73/83 2 years 1 aMCI 
Brys, 2009 65 T-tau 68/91 2 years 1 aMCI 
Hansson, 2007 
[41] 131 
 Aβ1-
42/Aβ1-40 
87/78 4-6 years 1 aMCI 
Hansson, 2007 131 Aβ1-42 93/53 
4-6 
years 1 aMCI 
Herukka, 2005 
[46] 78 Aβ1-42 70/76 4 years 1 MCI 
Herukka, 2005 78 Aβ1-42/P-tau 61/88 4 years 1 MCI 
Herukka, 2005 78 P-tau 87/60 4 years 1 MCI 
Herukka, 2005 78 T-tau 87/56 4 years 1 MCI 
Hansson, 2006 
[72] 134 
Aβ1-42 &T-
tau 95/83 
4-6 
years 2 aMCI 
Hertze, 2010 
[73] 159 Aβ1-42 90/71 
4.7 
years 2 MCI 
Hertze, 2010 159 Aβ1-42 &T-tau 88/82 
4.7 
years 2 MCI 
Hertze, 2010 159 P-tau 42/90 4.7 years 2 MCI 
Hertze, 2010 159 T-tau 73/77 4.7 years 2 MCI 
Mattsson, 2009 
[74] 750 Aβ1-42 79/65 ≥2 years 2 MCI 
Mattsson, 2009 750 Aβ1-42 , T-tau & P-tau 83/72 ≥2 years 2 MCI 
Mattsson, 2009 750 P-tau 84/47 ≥2 years 2 MCI 
Mattsson, 2009 750 T-tau 86/56 ≥2 years 2 MCI 
Prestia, 2013 57 Aβ1-42 79/27 3 years 2 aMCI 
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ADNI [75] 
Prestia, 2013 
ADNI 57 T-tau 46/61 3 years 2 aMCI 
Prestia, 2013 
TOMC [75] 36 Aβ1-42 94/50 
2.2 
years 2 aMCI 
Prestia, 2013 
TOMC 36 T-tau 61/83 
2.2 
years 2 aMCI 
Vos, 2013 [76] 61 Aβ1-42 55/71 2 years 2 naMCI 
Vos, 2013 130 Aβ1-42 75/58 2 years 2 aMCI 
Vos, 2013 61 T-tau 60/78 2 years 2 naMCI 
Vos, 2013 130 T-tau 74/61 2 years 2 aMCI 
Vos, 2013 61 Aβ1-42/T-tau 90/54 2 years 2 naMCI 
Vos, 2013 130 Aβ1-42/T-tau 98/38 2 years 2 aMCI 
Abbreviations: Sens., sensitivity; spec., specificity; Aβ1-42, β-amyloid protein; P-tau, 
phosphorylated tau protein; T-tau, total tau protein; ADNI, Alzheimer's disease 
neuroimaging initiative; TOMC, Translational outpatient memory clinic; FU-time, 
follow-up time; MCI, mild cognitive impairment; aMCI, amnestic mild cognitive 
impairment; naMCI, non-amnestic mild cognitive impairment. 
Cut-off: 1 means that the optimal cut-off value for separating progressing and non-
progressing patients was found and used in the same data. Cut-off: 2 means that the 
cut-off value for separating progressing and non-progressing patients was pre-defined, 
either taken from the literature or derived from other data, e.g. by finding the optimal 
cut-off value for separating healthy controls from patients with manifest dementia. 
When combinations are shown, they are the best performing combinations from each 
paper. 
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2. Aim 
The objective of this thesis is to clarify the prognostic value of MCI and MCI 
subtypes in memory-clinic patients. 
• The aim of paper I was to evaluate the prognostic accuracy 
of three different cut-off levels for classifying MCI and MCI 
subtypes in relation to diagnosis of dementia syndrome after 
2 and 4–6 years. 
• The aim of paper II was to investigate the influence of years 
of age and education on the prognostic accuracy of MCI 
subtypes over a 2-year period. 
• The aim of paper III was to create data-driven individual-
based cognitive subtypes using LPA and investigate the 
derived classes not only in terms of conversion to AD 
dementia, but also in terms of conversion to vascular 
dementia of the subcortical type.  
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3. Patients and Methods 
3.1 Participants 
All participants were patients at the Sahlgrenska memory clinic, or healthy 
controls, and included in the prospective Gothenburg MCI study [38]. 
Consecutive patients were invited to participate in the Gothenburg MCI study 
if they were between 40 and 79 years of age and presented with self-reported 
and/or informant-reported cognitive decline with a duration of at least 6 
months, without obvious relation to somatic or psychiatric disorders or 
trauma. Healthy control participants were recruited mainly from information 
meetings about dementia and senior-citizen organizations, and were included 
using the same criteria, but without self-reported or observed cognitive 
decline. 
Examinations in the Gothenburg MCI study included methods from various 
modalities. The cognitive modality consisted of neuropsychological testing 
comprising speed and attention, learning and episodic memory, visuospatial 
functions, language functions, and executive functions. Further, blood and 
CSF were sampled, and all participants underwent brain magnetic resonance 
imaging examinations.  
3.2 Diagnostic procedures 
In the Gothenburg MCI study, the Global Deterioration Scale (GDS) [15,77] 
was used to determine the cognitive stage of the patients. The GDS describes 
seven stages, from cognitively and functionally normal (GDS 1), to very 
severe cognitive decline or severe dementia (GDS 7); in the Gothenburg MCI 
study GDS 1 (equivalent to cognitively healthy); GDS 2 (equivalent to very 
mild or subjective cognitive decline); GDS 3 (equivalent to MCI); and GDS 4 
(equivalent to mild dementia) were used [38]. Table 5. 
In the Gothenburg MCI study operationalization, GDS comprised the MMSE 
[78], the Clinical Dementia Rating (CDR) [79], Comparative Status Analysis 
(STEP) [80], and Investigation of Flexibility (I-FLEX), which is a short form 
of the executive interview EXIT [81]. Table 5. 
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Table 5. Rating on the global deterioration scale (GDS) in the Gothenburg 
MCI study 
 STEP I-FLEX CDR MMSE 
GDS 1 - cognitively healthy 0 0 ≤1 x 0.5 ≥29 
GDS 2 - very mild or subjective 
cognitive impairment 
0 <3 ≤1 x 0.5 ≥28 
GDS 3 - MCI ≥1 ≥3 >1 x 0.5 ≥26 
GDS 4 - mild dementia >1 >3 >1.0 ≤25 
Abbreviations: GDS, Global Deterioration Scale; STEP, Stepwise Comparative Status 
Analysis; I-FLEX, Investigation of flexibility; CDR, Clinical Dementia Rating; MMSE, 
Mini Mental State Examination; MCI, mild cognitive impairment. 
For GDS 2, cognitive complaints reported in clinical interview are mandatory. 
 
STEP combines neurologic and psychiatric examination methods and relies 
on observations made by a physician. It comprises 50 common dementia 
symptoms, and aims to determine a patient’s brain regional  symptom profile 
[80]. Eight items from the STEP tool (item 13. memory disturbance, 14. 
disorientation, 15. reduced capacity for abstract thinking, 16. visuospatial 
disturbance, 17. poverty of language, 18. sensory aphasia, 19. visual agnosia, 
and 20. apraxia) associated with dementia in general were used in the GDS 
assessment. In an inter-rater reliability analysis of the STEP [82], items 13-17 
and item 20 had kappa >0.8, item 19 had kappa 0.66, and item 18 had kappa 
0.4).  
The CDR [79,83] is a standardized clinical interview conducted with the 
patient and an informant. It covers memory, orientation, judgement and 
problem solving, community affairs, home and hobbies, and personal care. In 
the Gothenburg MCI study, a simplified version of CDR was used, where the 
rater used the clinical and anamnestic information available to score, however 
not results from the neuropsychological test battery. 
The MMSE [78] test was originally intended as a cognitive status test in 
psychiatry patients, and is frequently used in dementia and MCI research. 
The MMSE tests orientation, immediate recall, attention, delayed recall, 
language, and copying of pentagons. 
I-FLEX is an assessment of executive function, with 6 parts: a number-letter 
task (1A to 5E), a word fluency task (≥10 words in one minute considered 
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unimpaired), anomalous sentence repetition (5 sentences), an interference 
task (the word 'blue' in black letters, the patient has to correctly state the 
colour of the letters), 2 Luria hand sequences, and a counting task. 
For patients with GDS 4, the following criteria were used for an etiological 
dementia diagnosis: Alzheimer’s disease was diagnosed using the 1984 
National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s Disease and Related Disorders Association criteria for 
AD [84]. Vascular dementia forms are either SVD or cortical vascular 
dementia (cVaD). SVD was diagnosed using the Erkinjuntti criteria [85], and 
cVaD using the National Institute of Neurological Disorders and Stroke and 
Association Internationale pour la Recherché et l’Enseignement en 
Neurosciences criteria [86]. 
To date, no patients in the Gothenburg MCI study have progressed to a mix 
of AD and cortical vascular dementia (cVaD) [38]. A MixD diagnosis in the 
Gothenburg MCI study might be either a combination of AD and SVD or AD 
and cVaD, although the latter has been rare (one patient with AD/cVaD and 
two with AD and both cVaD and SVD at baseline, none among the 
converters). In both cases, the patient must also fulfill clinical AD 
symptomatology according to established criteria [84] (i.e., parietotemporal 
lobe syndrome). Additionally, white-matter changes must be either (1) 
moderate/severe, with no predominant frontal lobe syndrome or (2) mild, and 
in combination with a marked frontal lobe syndrome (in addition to the 
parietal lobe syndrome).  
3.3 Neuropsychological testing 
In the Gothenburg MCI study, a neuropsychological test battery was 
administered to patients and controls in each biennial study round. Some tests 
have been removed, added, or had their versions changed in the course of the 
study, often based on clinical considerations. A full description of the tests 
and the changes to the test battery over time is beyond the scope of this 
thesis.  
The test battery was administered by a licensed psychologist, or a 
psychologist-in-training supervised by a licensed psychologist during two 
sessions of 1 to 2 hours. The test order was standardized, and verbal tests 
were varied with nonverbal in each session. Tasks administered between 
immediate and delayed recall on the memory tests that should not influence 
performance on delayed recall were chosen. 
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The test battery was designed to cover the cognitive domains speed and 
attention, learning and episodic memory, visuospatial functions, language 
functions, and executive functions. In the full battery, several cognitive 
subfunctions were assessed within each cognitive domain. 
Episodic memory. The Rey Auditory Verbal Learning test (RAVLT) is a 
word-recall test considered to have a high test-retest reliability [87,88]. A 15-
item word-list is read to the patient five times, each time the number of 
recalled items is registered. Next, a 15-item distraction list is read to the 
patient, and then the patient is asked to repeat the original list. After 30 
minutes of distraction (i.e. other tests) delayed recall of the original items are 
registered, followed by a recognition task. The delayed recall trial was used 
in papers I-III. In the Wechsler's logical memory test (WLM) [89] the patient 
is read two short stories and asked to repeat them immediately and after 30 
minutes of distraction. The delayed recall trial was used in papers I and II. 
Speed and attention. In the Digit Symbol test (from the Wechsler Adult 
Intelligence Scale (WAIS), revised [90] or WAIS-III [91]), the patient enters 
symbols corresponding to numbers according to a symbol key. Number of 
correct items after 90 (WAIS-r version) or 120 seconds (WAIS-III version) 
are recorded. Both versions were used in paper I.  
In the Trailmaking test part B (TMT B) [92], the patient draws a line on a 
sheet of paper, from 1 to A, to 2, to B etc until they reach the final number 
13. The time required to complete the task is noted. TMT B is a test of 
complex alternating attention, and can also be construed as a test of executive 
function.  
Working memory or attention span. In Digit Span from the Wechsler Adult 
Intelligence Scale [90], the patient is asked to repeat series of digits of 
increasing length forward and backward. In paper III, the sum of the number 
of digits repeated forward and backward was used.  
Language functions. The controlled oral word association test (COWAT) F-
A-S is a test of letter-fluency, where the patient is asked to say as many 
words as they can in 60 seconds, starting with the letters F, A, and S, 
respectively, with certain exceptions [93]. In paper III, the sum of correct 
items for letters F-A-S were used. The Token test [94] is a test of language 
comprehension, where the patient is given verbal instructions on how to 
manipulate 10 plastic tokens, 5 circles and 5 squares with different colors. In 
papers I and II, a version with 22 items [95] was used. The Boston naming 
test (BNT) [96] is a test of naming ability, where the patient is presented with 
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sixty drawings of increasing difficulty. In paper I, items 30-60 were used, 
because items 1–29 were not administered to all patients [97]. 
Visuospatial functions. The copying task of the Rey complex figure test 
(RCF) [98] is a test of spatial orientation and construction. In papers I and II, 
the number of correct items copied were used. In the silhouettes subtest of the 
Visual Object and Space Perception battery (VOSP) [99], the patient is asked 
to identify 30 silhouettes of everyday objects and animals. The test measures 
spatial perception and was used in papers I-III.  
Executive functions. The parallel serial mental operations (PaSMO) [39] test 
entails the patient rattling off the Swedish alphabet from A to Ö, with each 
letter followed by its corresponding increasing number. The test is similar to 
a verbal version of TMT B, but without any visual aid. The test measures 
mental control. Response time in seconds was used in papers I-III. The 
Stroop color word test (Stroop III) is a test of inhibition of automated 
responses. The patient is asked to name the font color of a non-matching 
color word. Response time in seconds was used in papers I and II. In Table 6, 
the cognitive tests used in this thesis are listed. 
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Table 6. Neuropsychological tests used in paper I-III 
Neuropsychological domains and tests Paper   
 I II III 
Episodic memory    
RAVLT delayed recall (correct items) X X X 
WLM delayed recall (correct items) X X  
Speed and attention    
Digit Symbol WAIS-r (correct items after 90 seconds) X X  
Digit Symbol WAIS-III (correct items after 120 seconds) X X  
TMT B (response time in seconds) X X X 
Language functions    
COWAT F-A-S (correct items after 60 seconds per letter)   X 
Token test (correct items) X X  
BNT 30-60 (correct items) X   
Visuospatial functions    
RCF copy (correct items) X X  
VOSP silhouettes (correct items)  X X X 
Executive functions    
PaSMO II (response time in seconds) X X X 
Stroop III (response time in seconds) X X  
Working memory or attention span    
Digit span (items correct backward + forward)   X 
Abbreviations: RAVLT, Rey auditory verbal learning test; WLM, Wechsler logical 
memory; WAIS-r, Wechsler Adult Intelligence Scale revised; WAIS-III, Wechsler 
Adult Intelligence Scale third edition; TMT B, Trailmaking test part B; COWAT F-
A-S, Controlled oral word association test letters F-A-S; BNT, Boston naming test; 
RCF copy, Rey complex figure copying; VOSP silhouettes, the silhouettes subtest 
from the Visual Object and Space Perception battery; PaSMO II, Parallel serial 
mental operations part II. 
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3.4 Classification of MCI subtypes 
For the papers presented in this thesis, MCI subtypes were determined using 
neuropsychological test data, in accordance with Jak et al’s [21] typical 
criteria (Table 2), if not otherwise noted. aMCI-sd was operationalized as 
having at least one memory test score below the cut-off score, and all non-
memory domain test scores above; aMCI-md as having at least one memory 
test score as well as at least one non-memory test score below the cut-off 
score; naMCI-sd as having at least one test score in any non-memory domain 
below the cut-off score, and having both memory test scores above it; 
naMCI-md as having at least two test scores in any two or more non-memory 
domains below the cut-off score and having both memory scores above it. 
Further, all patients with any one test under the cut-off were also analyzed as 
non-subtyped MCI and patients with no test result under the cut-off were 
categorized as 'no impairment'. 
In paper I, we dichotomized the test results of the healthy controls based on 
age ≥ 65 and ≤ 64, and used the means and standard deviations in each group 
to classify patients. In paper II, we dichotomized only those test results where 
there were significant differences among the healthy controls when they were 
dichotomized based on age (≥65 or ≤64) and education (≥13 or ≤12) and used 
the means and standard deviations in each group to classify patients. Tests 
with no significant differences in the control group were not dichotomized. In 
paper I and II, we used percentiles rather than standard deviations to classify 
the patients. In paper III, we used regression-based formulas to calculate 
individual z-values controlled for years of age and education, which were 
then used to categorize each patient according to criteria mentioned above. 
In paper I, our MCI classifications correspond to the liberal, typical, and 
conservative criteria suggested by Jak et al. (2009). In paper II and III, our 
classification of MCI corresponds to the typical criteria. 
3.5 Cerebrospinal fluid AD-markers and APOE 
CSF and APOE data were only used in paper III. All CSF samples were 
collected by lumbar puncture in the L3/L4 or L4/L5 interspace at the 
standardized time point 8.30–9.00 am. The first 12 mL of CSF was collected 
in a polypropylene tube and immediately transported to the local laboratory 
for centrifugation at 2.000 × g at + 4◦ C for 10 min. The supernatant was 
pipetted off, gently mixed to avoid possible gradient effects, and aliquoted in 
polypropylene tubes that were stored at –80◦C pending biochemical analyses, 
without being thawed and re-frozen. 
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Blood samples were drawn in the morning in the fasted state. Plasma samples 
for determination of APOE concentrations were stored at –80◦C pending 
biochemical analyses, without being thawed and re-frozen. 
3.6 Statistical methods 
Differences in continuous variables were tested with the Tukey-Kramer HSD 
test for multiple comparisons (papers I-III), differences in categorical 
variables were tested with the chi-square test for dichotomous comparisons 
(paper II) or the Steel-Dwass for multiple comparisons (papers I-III). 
In paper III, we performed multiple logistic regression to confirm results 
from estimates of sensitivity and specificity while controlling for years of age 
and education.  
In paper III, LPA was performed using Mplus software (version 7.1). LPA is 
an individual-based analytic approach, which means that it analyzes patterns 
of values on variables within each individual participant, rather than patterns 
among the variables themselves, as in the more traditional variable-based 
analytic approach. LPA is a sub-class of mixture modelling. Mixture 
modelling is considered an individual-centered approach, and factor models, 
or variable-based models, are not actually competing but complementary 
perspectives or approaches. Mixture models can be used to find latent 
(unobserved) groups of individuals with measurement patterns that are 
similar to each other, and factor analysis looks for latent or unobserved 
variables assumed to underpin measurements on groups of variables [100]. 
LPA uses maximum likelihood estimation to model the classification 
uncertainty of the individual to a latent class, and the choice of number of 
clusters is considered less arbitrary than in cluster analysis using k-means 
clustering [101]. 
The various items on the MMSE do not necessarily have the same value, e.g. 
a score of 0 on the delayed recall item may not mean the same thing as a 
score of 0 on the comprehension item. MMSE also displays a pronounced 
roof effect when used in individuals with normal cognitive functioning or 
even mild cognitive impairment; it has a negative skew. However, in using 
MMSE descriptively, as was the case in papers I-III, parametric statistics (the 
Tukey-Kramer HSD test) were applied to test for differences across 
subgroups. Differences in years of education were also tested with parametric 
tests when used descriptively in papers I-III. Parametric statistical methods 
have been shown to be robust for use in data that is not normally distributed, 
and in ordinal data [102]. 
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3.6.1 Evaluation of diagnostic tests 
Table 7. Confusion matrix 
 Outcome (e.g. progression to dementia)  
 Outcome positive Outcome negative  
Test (e.g. MCI)    
Test positive True positive (TP) False positive (FP) = TP + FP 
Test negative False negative 
(FN) 
True negative (TN) = FN + TN 
 = TP + FN = FP + TN n = TP + FN + FP + TN 
Abbreviations: MCI, mild cognitive impairment; TP, true positive; FP, false positive; FN, 
false negative; TN, true negative. 
 
In order to evaluate the prognostic accuracy of a binary diagnostic test, we 
first determine the number of true positive, false positive, false negative, and 
true negative observations. A true positive observation is one where the test 
(e.g. does the patient have MCI or not) is positive, and the outcome (e.g. did 
the patient progress to dementia) is also positive. A false positive observation 
is one where the test is positive, and the outcome is negative. A false negative 
observation is one where the test is negative, and the outcome is positive. A 
true negative observation is one where both the test and the outcome are 
negative. Table 7. 
Sensitivity is calculated by dividing the number of true positive observations 
by the number of positive outcomes. Sensitivity tells us the percentage of 
patients with a positive outcome that are correctly identified by the test. 
Specificity is calculated by dividing the number of true negative observations 
with the number of negative outcomes. Specificity tells us the percentage of 
patients with a negative outcome that are correctly identified by the test. 
The positive likelihood ratio (LR+) is calculated by dividing sensitivity by 
the false positive rate (FP / (FP + TN)). The LR+ tells us the magnitude of 
multiplication of the odds of having a positive outcome when the test is 
positive, as compared to the odds of a positive outcome before any test is 
applied. 
The negative likelihood ratio (LR-) is calculated by dividing the false 
negative rate (FN / (TP + FN)). The LR- tells us the magnitude of 
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multiplication of the odds of having a positive outcome when the test is 
negative, as compared with the odds of a positive outcome before any test is 
applied.  
The pre-test probability of having a positive outcome is the same as the 
prevalence (outcome positive / n). Odds can be calculated from probabilities 
by dividing probability by (1 - probability); probability can be calculated 
from odds by dividing the odds by (1 + odds).  
The clinical utility index for a positive test (CUI+) is calculated by 
multiplying the sensitivity and the positive predictive value (PPV = TP / test 
positive) of a test. The clinical utility index for a negative test (CUI-) is 
calculated by multiplying the specificity and the negative predictive value 
(NPV = TN / (FP + TN)) of a test. The CUI was developed as an alternative 
to likelihood ratios and takes prevalence into account. CUI+ and CUI- can be 
interpreted as a test having excellent (≥ 0.81), good (≥ 0.64), satisfactory (≥ 
0.49), or poor (< 0.49) clinical utility [103]. 
In papers I-III, the number of true positive, false positive, false negative, and 
true negative observations are reported for each condition, along with 
corresponding sensitivity, specificity, and likelihood ratios. In papers I and II, 
pretest probability (or prevalence) and post-test probabilities for a positive 
and a negative test are also reported. In paper II, CUI+ and CUI- [103] are 
also reported. In paper II, a graphic method for comparing diagnostic tests 
was used [104]. With this method, the true positive rate is plotted over the 
false positive rate. 
When true and false positives and negatives are reported, the reader has the 
opportunity to calculate all the desired parameters of prognostic accuracy 
themselves. 
3.7 Ethical considerations 
The Gothenburg MCI study was approved by the local ethics committee 
before start of data-collection (diary number: L091-99, 15 March 1999) and 
again after protocol changes (diary number: T479-11, 8 June 2011). Written 
informed consent was obtained from all participants upon inclusion. 
The title of the updated application from 2011 was "Early detection of 
dementia and its impact on the understanding of the nature of the dementia 
disorders and their treatment" (author’s translation from Swedish). Further, 
the primary research aim was "to attempt to identify the most common 
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dementia disorders in a very early phase, i.e. before patients display the 
clinical picture currently required for a diagnosis of dementia to be given." 
(author’s translation from Swedish). Papers I-III fall within the scope of the 
ethical approval. 
At the Sahlgrenska memory clinic, neuropsychological and clinical 
assessment is part of clinical routine. Sampling and analysis of CSF is also 
part of clinical routine, however in most cases not for patients with only 
subjective cognitive complaints. Genetic (APOE) testing is not part of 
clinical routine, and was performed exclusively for research purposes. 
Results of APOE testing were not shared with the participants. All 
assessments of the healthy controls were done exclusively for research 
purposes. 
Mild cognitive impairment - concepts, cut-offs, and clinical relevance 
24 
4. Results 
4.1 Paper I 
The main objective of paper I was to compare the prognostic accuracy of 
MCI and MCI subtypes at three different cut-offs: 1.0, 1.5, and 2.0 SD under 
the mean of a normal control group.  
At all three cut-offs, patients with aMCI-md had an increased risk of 
progressing to all-cause dementia. For aMCI-md, sensitivity increased and 
specificity decreased when the cut-off was lowered from 2.0 to 1.5 and 1.0 
SD. MCI without subtyping had a high sensitivity, but a low specificity at all 
three cut-offs. We further investigated which cognitive domain that was most 
predictive of all-cause dementia when combined with a memory impairment. 
When present together with memory impairments, impairments in 
speed/attention and executive function showed the best predictive values in 
general, but there was a lot of variation when cut-off and follow-up time 
differed. 
Our results suggest that aMCI-md is the only viable subtype for predicting 
dementia for follow-up times up to six years. Lowering the cut-off decreases 
the positive predictive value, and increases the negative predictive value of 
aMCI-md. None of the three cut-offs were clearly better than the other ones. 
aMCI-md was the most common subtype among patients progressing to AD 
dementia, to SVD, and to MixD. Further, the Petersen subtypes may fail to 
account in full for the neuropsychological differences between prodromal 
probable AD dementia and SVD. 
When using 2.0 SD as the cut-off for aMCI-md, although LR+ was high, 
sensitivity was low. Further, we question the utility of using 2.0 SD as the 
cut-off score to predict progression to dementia since clinical judgment 
would likely already suggest a high risk of deterioration for aMCI-md 2.0 
SD. It is also possible that patients with aMCI-md 2.0 SD already fulfill 
clinical dementia criteria. 
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4.2 Paper II 
The main objective of paper II was to estimate if and how the prognostic 
accuracy of aMCI-md differs between older and younger patients, and 
patients who have shorter and longer education. We found that the prognostic 
accuracy of aMCI-md among younger patients with more years of education 
was very good, and poor in the three remaining patient groups, the poorest in 
older patients with fewer years of education. Conversely, conversion rates to 
dementia were the lowest in younger patients with more years of education 
and the highest in older patients with fewer years of education. I.e., even if 
the risk of developing dementia is rather high among older patients with 
fewer years of education, testing positive for aMCI-md does not increase the 
probability by much, whereas younger patients with more years of education 
have a low pre-test probability of progressing to dementia, which is sharply 
increased if they test positive for aMCI-md. 
Figure 1. Prognostic accuracy of aMCI-md for progression to all-cause dementia 
after 2 years in the different demographic groups, true positive rate over false 
positive rate. Abbreviations: Young Edu+, age ≤64 and education ≥13; Young Edu-, 
age ≤64 and education ≤12; Old Edu+, age ≥65 and education ≥13; Old Edu-, age 
≥65 and education ≤12; aMCI-md, amnestic multi-domain mild cognitive 
impairment. 
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4.3 Paper III 
The established MCI subtypes do not distinguish between incipient dementia 
etiologies very well. It is unclear if latent cognitive profiles can distinguish 
between VaD-S (a combined group of SVD and MixD) and AD dementia at 
the incipient stage. In paper III, we therefore aimed to create LPA classes 
based on neuropsychological tests, and to investigate if they differed in terms 
of progression to dementia of different etiologies. 
The LPA resulted in two classes with impaired cognition (Moderate and 
Severe impairments) and two classes with normal cognition (Normal-Low 
and Normal-High cognition). Belonging to the Moderate class predicted 
progression to all-cause dementia and to AD; belonging to the Severe class 
predicted progression to all-cause dementia, AD and VaD-S. Of the Petersen 
MCI subtypes, only amnestic multi-domain MCI predicted progression to all-
cause dementia, AD, and VaD-S. 
There were more APOE e4 carriers in the Severe and the Moderate classes 
than in the Normal-low class. Further, T-tau was higher and Aβ1-42 was lower 
in the Severe and Moderate classes than in the two normal classes, but the 
biomarkers did not significantly differ between the Severe and the Moderate 
class. 
Latent cognitive profiles separated between AD and VaD-S, while the 
Petersen subtypes did not. However, similar to the Petersen subtypes, LPA 
classes work better for ruling out progression to dementia than for case 
finding. 
4.4 MCI subtype classification in paper I-III 
In paper I-III, slightly different methods were used for classifying MCI and 
MCI subtypes (as described in detail in section 3.4). In order to compare the 
three different operationalizations of having a test result ≥ 1.5 SD below 
healthy controls, Cohen’s kappa, a test of agreement, was estimated for the 
three methods, for all subtypes and for aMCI-md dichotomously. Table 8. 
These results are not presented in the papers. I also estimated sensitivity and 
specificity of aMCI-md as operationalized in the three different papers. Table 
9.  
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Table 8. Classification agreement in papers I-III  
MCI all subtypes Observed agreement Cohen’s kappa 
Paper I vs paper II 71% 0.63 
Paper I vs paper III 60% 0.47 
Paper II vs paper III 64% 0.52 
aMCI-md   
Paper I vs paper II 95% 0.85 
Paper I vs paper III 89% 0.66 
Paper II vs paper III 89% 0.67 
Abbreviations: MCI, mild cognitive impairment; aMCI-md, amnestic 
multi-domain MCI; vs, versus. 
 
Table 9. Prognostic accuracy of the aMCI-md classifications in papers 
I-III 
aMCI-md Sensitivity Specificity LR+ LR- 
Paper I 69 (55-80) % 83 (78-87) % 4.1 (3.0-5.6) 0.4 (0.3-0.6) 
Paper II 66 (52-78) % 86 (82-90) % 4.8 (3.4-6.8) 0.4 (0.3-0.6) 
Paper III 63 (49-75) % 90 (86-94) % 6.5 (4.2-10.0) 0.4 (0.3-0.6) 
Abbreviations: aMCI-md, amnestic multi-domain mild cognitive impairment; LR+, 
positive likelihood ratio; LR-, negative likelihood ratio. 
 
There is no universally accepted interpretation of the magnitude of Cohen’s 
kappa, however it has been suggested that <0.00 could be interpreted as poor 
agreement, 0.00–0.20 as slight agreement, 0.21–0.40 as fair agreement, 0.41–
0.60 as moderate agreement, 0.61–0.80 as substantial agreement, and 0.81–
1.00 as almost perfect agreement [105]. With these figures as a guideline, the 
agreement between our own MCI subtype operationalizations can be 
interpreted as moderate to substantial, and the agreement between the aMCI-
md operationalizations as substantial to almost perfect. Arguably, aMCI-md 
is the most important subtype to classify correctly, and the differences in 
operationalization produced results with a high level of agreement for this 
construct. 
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Using the same data, different operationalizations may result in slightly 
different classifications of MCI and MCI subtypes, as well as different 
accuracy in predicting progression. Using regression to estimate the influence 
of e.g. age and education or other variables of interest is probably more 
accurate than dichotomizing the control group, and further allows for keeping 
the full control group data set as comparison for all patients. Further, what a 
neuropsychological test measures, is somewhat unclear, and test choice likely 
influences all parameter estimates. We did not use the same 
neuropsychological tests, and we did not operationalize the cut-off in the 
same way, in the three papers, but all three papers adhered to the typical 
criteria (Table2) [21]. Thus, many different operationalizations of MCI can 
be used while still fulfilling general criteria. 
This section highlights some of the problems inherent in MCI and dementia 
research. Differences in operationalization occur on many levels, apparently 
even within the thesis of a single person. How many tests are required to be 
impaired, how many tests are used, which tests are used, to what domain do 
you ascribe a test, what level of impairment is required (1.0, 1.3, 1.5, 2.0 SD 
etc.), and how do you operationalize the level of impairment (using published 
norms, or a healthy control group etc.), plus of course inclusion and inclusion 
criteria and procedures affect the make-up of the data-set.  
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5. Discussion 
The objective of this thesis was to clarify what the prognostic value of MCI 
and MCI subtypes is in memory-clinic patients. MCI as defined by widely 
used criteria [17,20] has little prognostic value on its own. Amnestic multi-
domain MCI can have clinical utility as a negative test, i.e. to rule out 
progression to dementia in the near future. As a positive test, to find cases 
with a high probability of progressing to dementia, the clinical utility of MCI 
as defined by criteria, of any subtype, in all age- and education groups, is 
poor at best (clinical utility index for a positive test result ≤ 0.49). 
No previous studies have investigated the prognostic accuracy of multiple 
cut-off points for defining MCI subtypes in memory-clinic patients. Jak et al 
[21] did investigate stability over time of several different operationalizations 
of MCI and MCI subtypes (see Table 3 for a description of the various 
operationalizations), but they applied the criteria in a group of neurologically 
normal community-dwelling older adults, and no one progressed to dementia 
during the follow-up time.  
It was previously unclear how the prognostic accuracy of MCI and MCI 
subtypes differed according to the age and education of patients. We have 
shown that the prognostic accuracy of particularly aMCI-md is superior in 
younger patients with more years of education in relation to other 
demographic groups. In two papers, Visser et al. concluded that the 
prognostic accuracy of aMCI is good only among memory clinic patients 
older than 65 [52] and older than 70 [53], respectively. Our results did not 
support this conclusion, and instead show that the prognostic accuracy of 
aMCI-md is better among younger than older patients. To a certain extent, 
the difference can be explained by difference in interpretation. Inon of the 
studies by Visser et al. [52], the PPV was higher in the older group, however 
the NPV was much higher in the younger group, as was the LR+ (LR+ 12.8 
in the age group 55-64, LR+ 2.1 in the age group 65-85. Author’s own 
calculations). Thus, the results in Visser (2005) can be interpreted as being in 
congruence with our results, with a better prognostic accuracy among 
younger patients. In the other paper by Visser et al. [53], sensitivity, 
specificity, and PPV were higher among patients aged 70-85 than patients 
aged 55-69, and PPV was very low among patients aged 40-54. However, 
NPV was higher among younger patients, and the highest in the youngest 
group. There is no clear reason for the differences between Visser’s and our 
results. The mean age for the patients with aMCI was 62, as compared with 
our patient mean age of around 65 for all MCI patients. 
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Our results are in congruence with Chary et al. [106], who in a population-
based study showed that neuropsychological test results predicted all-cause 
dementia in participants with higher but not lower education level. No 
previous studies have investigated the influence of both patient age and 
education on the prognostic accuracy for progression to dementia. 
Several studies have reported data-driven cognitive subtypes in memory-
clinic patients, using either various cluster-analysis techniques, or latent 
profile analysis. The studies using LPA reported 3 [67,68], 5 [66], and 7 [65] 
classes, with groups largely similar to our classes; one or two groups 
displaying normal cognitive test scores; one or two groups with 
predominantly memory impairments, resembling our Moderate group, and 
one mixed group, similar to our Severe group. However, Köhler et al. [66] 
also identified a non-amnestic group with impairments in other domains, 
which we did not. We identified two impaired groups, both with memory test 
scores at or below -1.5 z, much like Eppig et al. [68]. Three studies using 
LPA reported progression data, Eppig et al. [68] to all-cause dementia, and 
Köhler et al. [66] also to other etiologies, but not to subcortical vascular 
dementia, and McGuinness et al. [67] to all-cause dementia. Thus, our results 
are the first reporting a difference in prognostic accuracy for statistically 
derived subgroups in prognostic accuracy for progression to AD and SVD 
dementias. 
Studies investigating the prognostic accuracy of AD biomarkers and 
combinations of biomarkers are typically performed in patients with MCI, 
either according to Petersen’s criteria from 1999 [17] (i.e. aMCI) or the 
updated criteria [20]. Table 4. This likely affects the results obtained. Even if 
it is unusual, some help-seekers who present without cognitive impairments 
still progress to dementia, and help-seekers without cognitive impairments 
but with positive AD biomarkers may have an increased risk of progressing 
to dementia [107]. And even though the comparison may be questionable 
because of differences in both outcome measures and inclusion criteria, 
sensitivity and specificity for aMCI-md (sensitivity 69% and specificity 83% 
for progression to all-cause dementia after 2 years, paper I) is not very 
different from the sensitivities and specificities reached using biomarkers in 
MCI patients (Table 4). Further, it can be argued that CSF biomarkers 
represent a more costly, more invasive, less widely available, and less 
tolerated option, resulting in a modest increase in prognostic accuracy at best 
[70,108]. 
Few studies on MCI and dementia use criteria for SVD. White-matter 
changes are often accepted as a part of AD, or may be described as atypical 
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AD, although there are data supporting the notion that SVD is a non-AD 
disorder [109]. Results from paper III and previous results from our group 
[110] show that dementia with subcortical features may be phenotypically 
and pathophysiologically different from AD. 
5.1 Problematization of the MCI concept 
The clinical relevance of the MCI concept can be questioned, since its utility 
in identifying patients likely to progress to dementia even within the near 
future is poor. Widely used criteria may, however, be used to identify patients 
with a very low probability (around 1 %, depending on cut-off choice) of 
progressing to dementia. It could be argued that giving a patient an MCI 
diagnosis is helpful in that it confirms the patient’s own perception of 
cognitive decline. However, if this is the goal, perhaps a new set of criteria 
should be developed to this end. Since the MCI diagnostic entity gives little 
attention to functional impairments, only stating that these may not be severe 
enough to warrant a dementia diagnosis, criteria intended to capture the 
patient’s own perceptions of impairment should pay more attention to 
instrumental activities of daily living as well. If MCI or a similar diagnostic 
entity (e.g. mild neurocognitive disorder) is to be applied in patient groups 
other than memory-clinic patients, e.g. younger patients with stress-induced 
cognitive impairments, taking functional impairments of a lesser magnitude 
into account may be of great importance. For example, difficulties with 
paying bills or maintaining the household may cause significant suffering for 
someone in their 40s. 
Mental disorders are usually associated with either significant distress or 
disability [1,22,111]. MCI is defined by the absence of functional 
impairments severe enough to impede independence in functional abilities. 
Further, in the DSM V, it is stated that 
"The diagnosis of a mental disorder should have clinical utility: it should 
help clinicians to determine prognosis, treatment plans, and potential 
treatment outcomes for their patients. However, the diagnosis of a mental 
disorder is not equivalent to a need for treatment." 
However, MCI may not meet this criterion, since it may not help the clinician 
to determine a patients prognosis, other than in its absence [112]. In 
combination with CSF and imaging biomarkers, a better prognostic accuracy 
could possibly be achieved, it has, however, not been unequivocally shown. 
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In the Gothenburg MCI study, a lot of patients opt out of the study after a few 
years (44% drop-out at the 6-year follow-up) [38]. However, progression to 
dementia seems to occur mostly within the first couple of years of the first 
visit [34,36,38]. Further, it can be argued that the first couple of years after 
first visit are also the most clinically important. Longer follow-up periods are 
important to understand the phenomena better, they are, however, notoriously 
difficult to carry out without significant loss to follow-up. 
5.2 Societal impact of dementia 
Though dementia diagnoses will certainly increase as populations across the 
world grow older, there is also accumulating evidence that incidence rates of 
dementia are falling, possibly due to e.g. better management of 
cardiovascular disease, improvements in education, healthcare etc. [113,114]. 
The results suggest improved healthcare early in life might benefit late-life 
cognitive health, and possibly reduce the risk of dementia. Further, dementia 
prevalence is still very low in the age groups studied in a typical memory-
clinic research setting [115].  
Estimates from Eurostat show that the population above 80 will increase, 
whereas the population between 50 and 80 (now target population in memory 
clinics and research) will start to decrease as early as 2025 [117]. In those 
over 80, we also start seeing a dramatic increase in prevalence, from around 
7% among those aged 75-79, to 13% among those aged 80-84, and then 
sharply increasing to 43% among those aged 90+ [115].The focus of memory 
clinics and the research conducted in memory clinics is typically on younger 
patients. Are we focusing on the right population? Some argue that we do not 
[116]. 
5.3 Evaluating diagnostic tests 
The proper evaluation of a diagnostic test is a long-standing problem in 
medicine, and sensitivity, specificity, and likelihood ratios are not always 
easy to interpret [118].  
It has been argued that the likelihood ratios are more useful for comparing 
tests, but more difficult to understand  [119]. Another option, put forward by 
Biggerstaff [104], is graphically comparing tests. This method enables a 
simultaneous evaluation of several parameters of two or more binary 
diagnostic tests. When comparing two tests, they can be interpreted in 
relation to each other based on the position of their respective intercepts. 
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What is a desirable level of prognostic accuracy? This is difficult to say, and 
depends in part on the prognostic accuracy of competing markers or 
categorizations. A consensus report on molecular and biochemical markers of 
AD published in 1998 [120] suggested that a marker with sensitivity and 
specificity over 80% was desirable. However, a marker or categorization with 
e.g. both sensitivity and specificity of 85% would theoretically falsely tell 
15% of patients with the disease that they do not have it, and likewise tell 
15% of all patients without the disease that they do have it. The acceptability 
of such performance can be questioned, however it must be put into the 
context of what other categorizations are available to the clinician. If 85/85 is 
the best test available, then it is perhaps acceptable, or at least better than not 
being able to give any scientifically based prognosis at all.  
Which value is more important, sensitivity or specificity? This depends on 
the setting, and the purpose of the classification. In a primary-care setting, a 
high sensitivity might be more important than a high specificity. I.e., we do 
not want to convey a message of low risk to a patient who actually does 
progress to dementia within a couple of years of the assessment. In 
recruitment to clinical trials, which often takes place at memory-clinic units, 
a high specificity might take precedent over a high sensitivity. It could be 
argued that it is unethical to administer an experimental drug treatment to a 
patient who does not actually have the disease in question, with the risks 
involved in terms of adverse effects, the costs, and the time and effort a 
participant in a clinical trial is required to spend. This does, however, raise 
the question of what we consider disease in this context. Is disease the 
display of biological markers associated with the manifest stage of the 
respective disease categories, but perhaps with a small or unknown likelihood 
of progression of symptom severity? Or is the disease the very high 
likelihood of imminent progression of symptom severity to the point of loss 
of independence of living? I.e., is the disease the biological substrate, or is it 
the symptom severity? Given the pervasive uncertainty of the biological 
mechanisms behind AD and other dementia disorders, and the fact that 
clinical criteria define disease as a syndrom of a certain severity, I argue that 
the latter is the case. This would mean that recruitment to clinical trials needs 
to be based not only on biological measurements, but more so on the display 
of characteristics associated with a high likelihood of progression of 
symptom severity. 
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6. Conclusions 
Patients who do not meet standard criteria for MCI have a very low 
probability of progressing to dementia. The only MCI subtype that 
significantly increases the probability of progressing to dementia is aMCI-
md. Prognosticating progression to dementia is easier in patients under 65 
with more than 12 years of education than in other demographic groups. 
However, even among younger patients with more years of education, it 
may be better to use absence of amnestic multi-domain MCI to rule out 
progression to dementia than to use presence of amnestic multi-domain MCI 
to find patients who will progress. Cognitive profiles derived using LPA may 
be better suited for discriminating between those who progress to AD 
dementia and those who progress to VaD-S, than the traditional MCI 
subtypes. 
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7. Future perspectives 
The most pressing issue in the field of MCI and dementia research is that of 
finding treatments for the most common underlying diseases. Further, there is 
still a lack of consensus surrounding MCI, how it should be operationalized, 
and with what instruments. 
The clinical value of MCI is supposedly its ability to predict progression to 
dementia. If MCI, or mild neurocognitive disorder as it is called in the latest 
iteration of the DSM [22], is to be used in other populations than memory-
clinic patients worried about developing dementia, perhaps a different 
diagnostic category should be formulated, outlining subjective and objective 
level of cognitive decline, as well as level of functional impairment, and the 
distress experienced by the patient.  
Simultaneously, continued efforts are needed to formulate a category that has 
a better prognostic accuracy for progression to dementia than current 
concepts. However, MCI is still the best described of the various attempts to 
identify patients at a pre-dementia stage. 
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